Prevention of Contrast Nephropathy by Sodium Bicarbonate Versus Sodium Chloride and N-acetylcysteine
1 other identifier
interventional
250
1 country
1
Brief Summary
The objective of this study is to assess the efficacy of sodium bicarbonate compared with sodium chloride and oral N-acetylcysteine (NAC ) pretreatment for prevention of contrast nephropathy in patients with advanced renal disease undergoing cardiac catheterisation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jan 2005
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2005
CompletedFirst Submitted
Initial submission to the registry
July 17, 2006
CompletedFirst Posted
Study publicly available on registry
July 18, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2008
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2009
CompletedFebruary 25, 2010
February 1, 2010
3 years
July 17, 2006
February 24, 2010
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The incidence of contrast induced nephropathy, defined as 25% or more increase in serum creatinine within 2 days of contrast administration, will be assessed.
Interventions
Eligibility Criteria
You may qualify if:
- Eligible patients include individuals aged 18 year or older with GFR 15-60ml/min calculated by MDRD formula, who were scheduled to undergo cardiac catheterization. During the randomized study, consecutive eligible patients scheduled for exposure to the nonionic radiographic contrast agent iopamidol (796 mOsm/kg H2O, 755 mg of iopamidol per milliliter, and 370 mg iodine per milliliter) will be considered for enrollment.
You may not qualify if:
- i. Serum creatinine levels more than 8mg/dl or GFR less than 15ml/min
- ii. Change in serum creatinine levels of ³0.5mg/dl during the previous 24 hours.
- iii. Preexisting dialysis
- iv. Multiple myeloma.
- v. Pulmonary edema.
- vi. Uncontrolled hypertension (treated systolic blood pressure more than 160 mmHg, or diastolic blood pressure more than 100mmHg.)
- vii. Emergency catheterization.
- viii. Recent exposure to radiographic contrast (within two days of the study).
- ix. Allergy to radiocontrast.
- x. Pregnancy.
- xi. Administration of dopamine, mannitol or NAC before the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Shaare Zmc
Jerusalem, 91031, Israel
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
linda shavit, md
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
July 17, 2006
First Posted
July 18, 2006
Study Start
January 1, 2005
Primary Completion
January 1, 2008
Study Completion
May 1, 2009
Last Updated
February 25, 2010
Record last verified: 2010-02